Clinical genetic testing began over 30 years ago with the availability of mutation detection
for sickle cell disease diagnosis. Since then, the field has dramatically transformed to …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

Importance Whole-genome sequencing (WGS) is increasingly applied in clinical medicine
and is expected to uncover clinically significant findings regardless of sequencing indication …

Adverse drug reactions can be caused by a wide range of therapeutics. Adverse drug
reactions affect many bodily organ systems and vary widely in severity. Milder adverse drug …

Objective To test the hypothesis that ticagrelor plus aspirin is safe and superior to
clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence …

Polymorphisms in the cytochrome P (CYP) 450 family may cause adverse drug responses in
individuals. Cytochrome P450 2C19 (CYP2C19) is a member of the CYP family, where the …

Background The role of the CYP 2C19 genotype on clopidogrel efficacy has been studied
widely, with data suggesting reduced clopidogrel efficacy in loss‐of‐function variant carriers …

Genetic variation in the cytochrome P450 2C19 (CYP2C19) gene has been documented
gradually as the determinant conversion and variability in the antiplatelet effect of …

The time is ripe to assess whether pharmacogenomics research—the study of the genetic
basis for variation in drug response—has provided important insights into a personalized …

Aim Adverse drug events lead to increased morbidity, mortality and health care costs.
Pharmacogenetic testing that guides drug prescribing has the potential to reduced adverse …